Porvair Acquires J.G. Finneran Associates Inc
Porvair Sciences is pleased to welcome J. G. Finneran Associates into the Porvair family following its acquisition by Porvair plc.
Based in Vineland, New Jersey, J. G. Finneran designs, manufactures and distributes specialist laboratory consumables including vials, fi lters, microplates, closures and ancillary products. Finneran products clearly complement the biotechnology and chromatography product lines of Porvair Sciences and the combined product ranges will provide an enhanced offering to all customers.
There is a good fi t and synergy between the J.G. Finneran and Porvair Sciences businesses with Finneran bringing glass, plastics and assembly manufacturing capabilities as well as strong US distribution. This complements the strong UK based manufacturing and distribution capabilities of Porvair Sciences and together the businesses have a broad product offering for chromatography, sample preparation and environmental laboratories.
Both companies have a strong history of innovation and this will continue with emphasis on developing unique solutions for sample preparation in biotechnology and chromatography applications based around their core vial, microplate and fi ltration capabilities. Customers will benefi t from Porvair Sciences products being manufactured, stocked and distributed from J. G. Finneran’s facility in Vineland USA, as well as Finneran products being distributed from Wrexham UK. This is an exciting time in the development of both companies who look forward to achieving signifi cant growth in the international scientifi c laboratory marketplace.
42360pr@reply-direct.com
Thermo Fisher Scientifi c Broadens Science World in Germany
Science World, the Fisher Scientifi c Laboratory Experience, broadened its audience in Germany by going to Kap Europa, Messe Frankfurt on 9 May. The event, hosted by Thermo Fisher Scientifi c, showcased the latest in laboratory innovations available through the Fisher Scientifi c channel. Thousands of products were available for attendees to experience, making it an ideal event for anyone working in or around a laboratory.
Highlights from Science World included one of the best-known science journalists in Germany, Ranga Yogeshwar, who presented a keynote speech entitled ‘Innovation: Next Exit Future’; Physikanten & Co, who delivered a number of scientifi c experiments throughout the day; a comprehensive seminar programme that covered 24 topics and the new addition of having a Life Science Workfl ow room and Safety and Cleanroom Environment Solutions room.
Ranga Yogeshwar
Leading the way in serving science, the event attracted 418 delegates from as far afi eld as Cologne, Heidelberg, Aachen, Lübeck, Karlsruhe and Mannheim as well as bringing 50 leading suppliers together.
“Frankfurt is important because we have a good mix of different customers here. We have the big Pharmaceutical customers, the big Universities and other customers condensed in one area.
Frankfurt is defi nitely a hot-spot for science,” said Frank Schestag, Sales Director for the Fisher Scientifi c channel in Germany.
To participate in the post-Science World conversation, visit
www.facebook.com/ fi sherscientifi ceu and
www.twitter.com/ FisherSciEU using the hash tag #InspireScience
42778pr@reply-direct.com
Installation adds Scale-Up Capability for Antibody Production
BioInvent International AB, developers of immuno-regulatory antibodies for cancer treatment is upgrading and expanding its drug manufacturing operations with a full line of Merck’s Mobius®
single-use bioreactors, adding 3L, 50L, 200L and 1000L bioreactors to its upstream facility in Lund, Sweden.
“Our complete portfolio of single-use technologies addresses the needs of both emerging biopharmaceutical companies and established drug developers like BioInvent as they seek to increase productivity,” said Udit Batra, Member of the Merck Executive Board and CEO of the life science business sector of Merck. “We are providing a full range of bioreactors, services and support which will help BioInvent accelerate innovative therapeutics through the development pipeline.”
The upgrade of the BioInvent facility to include a 1000-litre single-use bioreactor will allow the company to meet production requirements for both its own novel antibody development projects and also those of customers they serve around the world.
“BioInvent has been discovering and manufacturing antibodies for more than 30 years, and when we decided to upgrade our single-use production facility, we established very demanding requirements,” said Kristoffer Rudenholm Hansson, vice president of Technical Operations at BioInvent. “Merck’s single-use bioreactors most effectively addressed our current and future needs with a fully scalable system.”
42621pr@reply-direct.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140 |
Page 141 |
Page 142 |
Page 143 |
Page 144 |
Page 145 |
Page 146 |
Page 147 |
Page 148 |
Page 149 |
Page 150 |
Page 151 |
Page 152 |
Page 153 |
Page 154 |
Page 155 |
Page 156 |
Page 157 |
Page 158 |
Page 159 |
Page 160 |
Page 161 |
Page 162 |
Page 163 |
Page 164 |
Page 165 |
Page 166 |
Page 167 |
Page 168 |
Page 169 |
Page 170 |
Page 171 |
Page 172
